Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen B Fox

Showing results (91-100 of 258) with videos related to

Pageof 26
Sort By:
Journal of the National Cancer Institute. Monographs|June 12, 2015
Neoadjuvant Model in Cancer Treatment: From Clinical Opportunity to Health-Care UtilityDaniele Generali, Stephen B Fox, Massimo Cristofanilli, et al.
European Journal of Cancer (Oxford, England : 1990)|May 11, 2016
Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: A literature based meta-analysis of randomized trialsGiandomenico Roviello, Sandra Sigala, Shahneen Sandhu, et al.
The Journal of Urology|February 22, 2011
Nuclear localization of factor inhibitor hypoxia-inducible factor in prostate cancer is associated with poor prognosisNadeem Shaida, Peter Chan, Helen Turley, et al.
Journal of Clinical Pathology|April 24, 2012
The molecular characterisation of unusual subcutaneous spindle cell lesion of breastElena A Takano, Toni-Maree Rogers, Richard J Young, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 7, 2011
Relationship between epidermal growth factor receptor status, p16(INK4A), and outcome in head and neck squamous cell carcinomaRichard J Young, Danny Rischin, Richard Fisher, et al.
British Journal of Cancer|December 26, 2022
Predicting response to immune checkpoint blockade in NSCLC with tumour-only RNA-seqJohn F Markham, Andrew P Fellowes, Thomas Green, et al.
Internal Medicine Journal|May 26, 2017
Survival difference according to mutation status in a prospective cohort study of Australian patients with metastatic non-small-cell lung carcinomaLavinia Tan, Marliese Alexander, Ann Officer, et al.
JCO Precision Oncology|February 1, 2022
MEK Inhibitor Therapy in Carcinomas With <i>RAF1</i> Fusions: Inferior Response in a Patient With Pancreatic Acinar Cell CarcinomaChristopher R McEvoy, Damien Kee, Owen W J Prall, et al.
Breast Cancer Research : BCR|April 10, 2013
HIF-1α stimulates aromatase expression driven by prostaglandin E2 in breast adipose stromaNirukshi U Samarajeewa, Fangyuan Yang, Maria M Docanto, et al.
Journal of the National Cancer Institute. Monographs|November 2, 2011
Molecular oncology and the neoadjuvant setting: the perfect blend for treatment personalization and clinical trial designDaniele Generali, Alfredo Berruti, Chiara Foroni, et al.
Pageof 26

Showing results (91-100 of 258) with videos related to

Sort By:
Pageof 26
Journal of the National Cancer Institute. Monographs|June 12, 2015
Neoadjuvant Model in Cancer Treatment: From Clinical Opportunity to Health-Care UtilityDaniele Generali, Stephen B Fox, Massimo Cristofanilli, et al.
European Journal of Cancer (Oxford, England : 1990)|May 11, 2016
Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: A literature based meta-analysis of randomized trialsGiandomenico Roviello, Sandra Sigala, Shahneen Sandhu, et al.
The Journal of Urology|February 22, 2011
Nuclear localization of factor inhibitor hypoxia-inducible factor in prostate cancer is associated with poor prognosisNadeem Shaida, Peter Chan, Helen Turley, et al.
Journal of Clinical Pathology|April 24, 2012
The molecular characterisation of unusual subcutaneous spindle cell lesion of breastElena A Takano, Toni-Maree Rogers, Richard J Young, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 7, 2011
Relationship between epidermal growth factor receptor status, p16(INK4A), and outcome in head and neck squamous cell carcinomaRichard J Young, Danny Rischin, Richard Fisher, et al.
British Journal of Cancer|December 26, 2022
Predicting response to immune checkpoint blockade in NSCLC with tumour-only RNA-seqJohn F Markham, Andrew P Fellowes, Thomas Green, et al.
Internal Medicine Journal|May 26, 2017
Survival difference according to mutation status in a prospective cohort study of Australian patients with metastatic non-small-cell lung carcinomaLavinia Tan, Marliese Alexander, Ann Officer, et al.
JCO Precision Oncology|February 1, 2022
MEK Inhibitor Therapy in Carcinomas With <i>RAF1</i> Fusions: Inferior Response in a Patient With Pancreatic Acinar Cell CarcinomaChristopher R McEvoy, Damien Kee, Owen W J Prall, et al.
Breast Cancer Research : BCR|April 10, 2013
HIF-1α stimulates aromatase expression driven by prostaglandin E2 in breast adipose stromaNirukshi U Samarajeewa, Fangyuan Yang, Maria M Docanto, et al.
Journal of the National Cancer Institute. Monographs|November 2, 2011
Molecular oncology and the neoadjuvant setting: the perfect blend for treatment personalization and clinical trial designDaniele Generali, Alfredo Berruti, Chiara Foroni, et al.
Pageof 26